New Limits Threaten EPA ’s Asbestos Review

After pushback from the chemical industry, President Donald Trump’s administration is scaling back a congressionally mandated review of asbestos and other deadly chemicals. Toxic minerals in widespread use will be excluded from the revamped Toxic Substances Control Act (TSCA), which last December included asbestos among the top 10 dangerous chemicals the Environmental Protection Agency (EPA) must review. Reducing the scope of the review will potentially leave millions of tons of asbestos and other toxic substances in homes and businesses. The Trump administration reportedly wants to limit risk evaluations of the top 10 toxic threats to new products being imported, sold or manufactured in the U.S. For asbestos, this means only a few hundred tons of the toxic mineral imported each year will be up for review, excluding nearly all of the estimated 8.1 million metric tons of asbestos-containing products currently in American infrastructure. Asbestos has not been manufactured in the U.S. since 2002, but imports nearly doubled from 2015 to 2016, according to a recent study by the Asbestos Disease Awareness Organization (ADAO) and the Environmental Working Group. The U.S. imported an estimated 705 metric tons of raw asbestos last year. The overwhelming majority of raw asbestos is used by chlorine manufacturers, but the toxic mineral is still used in certain vehicle braking systems, asphalt roof coatings and gaskets. Under the narrowed scope of the review, the EPA will only eval...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Tags: American Chemistry Council American Cleaning Institute American Petroleum Institute Asbestos Disease Awareness Organization asbestos exposure firefighters asbestos imports U.S. asbestos laws us Centers for Disease Control and Prevention Di Source Type: news

Related Links:

Malignant mesothelioma of the tunica vaginalis is a rare tumour which comprises less than 1% of all mesotheliomas.
Source: BMC Cancer - Category: Cancer & Oncology Authors: Tags: Case report Source Type: research
In this study, we took advantage of photodynamic therapy (PDT) to induce immunogenic cell death to generate mesothelioma cell lysates for DC priming and evaluated such a vaccine to treat peritoneal mesothelioma. We found that the white light in vitro activation of the photosensitizer OR141 led to mesothelioma cell death, together with the release of bona fide danger signals that promote DC maturation. The administration of a PDT-based DC vaccine to mice bearing peritoneal mesothelioma led to highly significant survival when compared with sham or control animals treated with anti-CTLA4 antibodies. This was further supported...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Revlon Inc. on Tuesday became the latest corporation hit with a lawsuit alleging asbestos-contaminated talc in its cosmetic products caused mesothelioma cancer in a woman. A Maryland couple filed the lawsuit in New York state court. Laura McDaniel believes her diagnosis of mesothelioma in January stems from her father’s earlier employment with Revlon, the multinational skin care, fragrance and cosmetics giant headquartered in New York City. She is seeking $20 million in compensatory damage and $40 million in punitive damages. Husband Edward McDaniel wants $5 million for mental anguish and loss of companionship. More ...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Three of the country’s leading cancer centers have opened a collaborative clinical trial that potentially could change surgical treatment of mesothelioma. Researchers will measure the safety and efficacy of using two different immunotherapy drug regimens — Opdivo (nivolumab) and Yervoy (ipilimumab) — beginning 42 days before surgery. The hope is that at least one will make surgical resection more effective. Sidney Kimmel Cancer Center at Johns Hopkins University, MD Anderson Cancer Center at the University of Texas and Greenebaum Cancer Center at the University of Maryland are working together to enroll a...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
CONCLUSION: In this contest, MacroH2A.1 overexpression supports its function as an epigenetic stabilizer that helps to establish and maintain differentiated states. PMID: 32077824 [PubMed - as supplied by publisher]
Source: Current Molecular Medicine - Category: Molecular Biology Authors: Tags: Curr Mol Med Source Type: research
Cellular Analytics, a biotechnology company in Ontario, Canada, has unveiled a novel liquid biopsy test for mesothelioma that could lead to more effective management of this rare cancer. The test has the potential to produce a much-earlier diagnosis of disease and the ability to personalize treatment and better predict a patient’s response to specific therapies. “We could change completely how this disease is viewed,” Dr. Brent Zanke, a specialist in diagnostic oncology and chief executive officer of Cellular Analytics, told The Mesothelioma Center at Asbestos.com. “It’s a proactive way to get...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Gene therapy is moving closer to becoming part of standard-of-care treatment for pleural mesothelioma, according to the latest multicenter clinical trial. The phase III trial, known as the INFINITE clinical research study, is designed to evaluate the intrapleural delivery of an investigational drug — a type of gene therapy — in combination with celecoxib and gemcitabine, anti-inflammatory and chemotherapy drugs, respectively. Researchers hope to stop, or at least slow, the growth of mesothelioma tumor cells with the combination therapy. “This is a very interesting concept,” oncologist Dr. Bernardo G...
Source: Asbestos and Mesothelioma News - Category: Environmental Health Authors: Source Type: news
Conditions:   Advanced Solid Tumors;   MSI-H/dMMR Tumors;   Cutaneous Squamous Cell Carcinoma;   Urothelial Carcinoma, HCC;   Cervical Cancer;   Esophageal Squamous Cell Carcinoma;   Merkel Cell Carcinoma, Small-cell Lung Cancer;   Mesothelioma;   PD-L1 Amplified Tumor (9p24.1);   Nasopharyngeal Carcinoma;   Cyclin-dependent Kinase 12 Mutated Tumors;   Basal Cell Carcinoma (Unresectable or Metastatic);   Sarcoma...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Malignant pleural mesothelioma (MPM) is a rare, aggressive tumor originating from mesothelial cells. It is associated with exposure to asbestos, mainly occupational, rarely environmental or domestic. Diagnosis is usually made at an advanced stage because symptoms are non-specific and late. The management of this tumor is challenging and outcome is poor. Therapeutic strategies are mainly based on surgery with curative intent or palliative cytotoxic chemotherapy. Few patients are candidates for surgery which must necessarily take into account numerous factors (i.e.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
More News: American Health | Asbestosis | Cancer | Cancer & Oncology | Centers for Disease Control and Prevention (CDC) | Chemistry | Environmental Health | Health and Safety | Internal Medicine | International Medicine & Public Health | Lawsuits | Legislation | Mesothelioma | Minerals | Occupational Health | Politics | Schools | Science | Study | Toxicology | Trump | USA Health